Selected research
Industry Research
Topical Drugs CDMO Industry Research Report 2026
Market perspective
The global Topical Drugs CDMO market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Topical Drugs CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Topical Drugs CDMO market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Topical Drugs CDMO market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Topical Drugs CDMO include Piramal Pharma Solutions, Pierre Fabre Group, PCI Pharma Services, MedPharm Ltd., Lubrizol Life Science, DPT Laboratories LTD., Contract Pharmaceuticals Limited, Cambrex Corporation and Bora Pharmaceutical CDMO and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Topical Drugs CDMO market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Topical Drugs CDMO.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Topical Drugs CDMO Market by Company
Piramal Pharma Solutions
Pierre Fabre Group
PCI Pharma Services
MedPharm Ltd.
Lubrizol Life Science
DPT Laboratories LTD.
Contract Pharmaceuticals Limited
Cambrex Corporation
Bora Pharmaceutical CDMO
Ascendia Pharmaceuticals
Topical Drugs CDMO Segment by Type
Contract Development
Contract Manufacturing
Topical Drugs CDMO Segment by Application
Semi-Solid Formulations
Solid Formulations
Liquid Formulations
Others
Topical Drugs CDMO Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Topical Drugs CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Topical Drugs CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Topical Drugs CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Topical Drugs CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Contract Development
- Contract Manufacturing
Applications
- Semi-Solid Formulations
- Solid Formulations
- Liquid Formulations
- Others
Companies covered
- Piramal Pharma Solutions
- Pierre Fabre Group
- PCI Pharma Services
- MedPharm Ltd.
- Lubrizol Life Science
- DPT Laboratories LTD.
- Contract Pharmaceuticals Limited
- Cambrex Corporation
- Bora Pharmaceutical CDMO
- Ascendia Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Topical Drugs CDMO by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Contract Development
- 2.2.3 Contract Manufacturing
- 2.3 Topical Drugs CDMO by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Semi-Solid Formulations
- 2.3.3 Solid Formulations
- 2.3.4 Liquid Formulations
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Topical Drugs CDMO Breakdown Data by Type
- 3.1 Global Topical Drugs CDMO Historic Market Size by Type (2021-2026)
- 3.2 Global Topical Drugs CDMO Forecasted Market Size by Type (2027-2032)
4 Topical Drugs CDMO Breakdown Data by Application
- 4.1 Global Topical Drugs CDMO Historic Market Size by Application (2021-2026)
- 4.2 Global Topical Drugs CDMO Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Topical Drugs CDMO Market Perspective (2021-2032)
- 5.2 Global Topical Drugs CDMO Growth Trends by Region
- 5.2.1 Global Topical Drugs CDMO Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Topical Drugs CDMO Historic Market Size by Region (2021-2026)
- 5.2.3 Topical Drugs CDMO Forecasted Market Size by Region (2027-2032)
- 5.3 Topical Drugs CDMO Market Dynamics
- 5.3.1 Topical Drugs CDMO Industry Trends
- 5.3.2 Topical Drugs CDMO Market Drivers
- 5.3.3 Topical Drugs CDMO Market Challenges
- 5.3.4 Topical Drugs CDMO Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Topical Drugs CDMO Players by Revenue
- 6.1.1 Global Top Topical Drugs CDMO Players by Revenue (2021-2026)
- 6.1.2 Global Topical Drugs CDMO Revenue Market Share by Players (2021-2026)
- 6.2 Global Topical Drugs CDMO Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Topical Drugs CDMO Head Office and Area Served
- 6.4 Global Topical Drugs CDMO Players, Product Type & Application
- 6.5 Global Topical Drugs CDMO Manufacturers Established Date
- 6.6 Global Topical Drugs CDMO Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Topical Drugs CDMO Market Size (2021-2032)
- 7.2 North America Topical Drugs CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Topical Drugs CDMO Market Size by Country (2021-2026)
- 7.4 North America Topical Drugs CDMO Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Topical Drugs CDMO Market Size (2021-2032)
- 8.2 Europe Topical Drugs CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Topical Drugs CDMO Market Size by Country (2021-2026)
- 8.4 Europe Topical Drugs CDMO Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Topical Drugs CDMO Market Size (2021-2032)
- 9.2 Asia-Pacific Topical Drugs CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Topical Drugs CDMO Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Topical Drugs CDMO Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Topical Drugs CDMO Market Size (2021-2032)
- 10.2 South America Topical Drugs CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Topical Drugs CDMO Market Size by Country (2021-2026)
- 10.4 South America Topical Drugs CDMO Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Topical Drugs CDMO Market Size (2021-2032)
- 11.2 Middle East & Africa Topical Drugs CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Topical Drugs CDMO Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Topical Drugs CDMO Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Piramal Pharma Solutions
- 12.1.1 Piramal Pharma Solutions Company Information
- 12.1.2 Piramal Pharma Solutions Business Overview
- 12.1.3 Piramal Pharma Solutions Revenue in Topical Drugs CDMO Business (2021-2026)
- 12.1.4 Piramal Pharma Solutions Topical Drugs CDMO Product Portfolio
- 12.1.5 Piramal Pharma Solutions Recent Developments
- 12.2 Pierre Fabre Group
- 12.2.1 Pierre Fabre Group Company Information
- 12.2.2 Pierre Fabre Group Business Overview
- 12.2.3 Pierre Fabre Group Revenue in Topical Drugs CDMO Business (2021-2026)
- 12.2.4 Pierre Fabre Group Topical Drugs CDMO Product Portfolio
- 12.2.5 Pierre Fabre Group Recent Developments
- 12.3 PCI Pharma Services
- 12.3.1 PCI Pharma Services Company Information
- 12.3.2 PCI Pharma Services Business Overview
- 12.3.3 PCI Pharma Services Revenue in Topical Drugs CDMO Business (2021-2026)
- 12.3.4 PCI Pharma Services Topical Drugs CDMO Product Portfolio
- 12.3.5 PCI Pharma Services Recent Developments
- 12.4 MedPharm Ltd.
- 12.4.1 MedPharm Ltd. Company Information
- 12.4.2 MedPharm Ltd. Business Overview
- 12.4.3 MedPharm Ltd. Revenue in Topical Drugs CDMO Business (2021-2026)
- 12.4.4 MedPharm Ltd. Topical Drugs CDMO Product Portfolio
- 12.4.5 MedPharm Ltd. Recent Developments
- 12.5 Lubrizol Life Science
- 12.5.1 Lubrizol Life Science Company Information
- 12.5.2 Lubrizol Life Science Business Overview
- 12.5.3 Lubrizol Life Science Revenue in Topical Drugs CDMO Business (2021-2026)
- 12.5.4 Lubrizol Life Science Topical Drugs CDMO Product Portfolio
- 12.5.5 Lubrizol Life Science Recent Developments
- 12.6 DPT Laboratories LTD.
- 12.6.1 DPT Laboratories LTD. Company Information
- 12.6.2 DPT Laboratories LTD. Business Overview
- 12.6.3 DPT Laboratories LTD. Revenue in Topical Drugs CDMO Business (2021-2026)
- 12.6.4 DPT Laboratories LTD. Topical Drugs CDMO Product Portfolio
- 12.6.5 DPT Laboratories LTD. Recent Developments
- 12.7 Contract Pharmaceuticals Limited
- 12.7.1 Contract Pharmaceuticals Limited Company Information
- 12.7.2 Contract Pharmaceuticals Limited Business Overview
- 12.7.3 Contract Pharmaceuticals Limited Revenue in Topical Drugs CDMO Business (2021-2026)
- 12.7.4 Contract Pharmaceuticals Limited Topical Drugs CDMO Product Portfolio
- 12.7.5 Contract Pharmaceuticals Limited Recent Developments
- 12.8 Cambrex Corporation
- 12.8.1 Cambrex Corporation Company Information
- 12.8.2 Cambrex Corporation Business Overview
- 12.8.3 Cambrex Corporation Revenue in Topical Drugs CDMO Business (2021-2026)
- 12.8.4 Cambrex Corporation Topical Drugs CDMO Product Portfolio
- 12.8.5 Cambrex Corporation Recent Developments
- 12.9 Bora Pharmaceutical CDMO
- 12.9.1 Bora Pharmaceutical CDMO Company Information
- 12.9.2 Bora Pharmaceutical CDMO Business Overview
- 12.9.3 Bora Pharmaceutical CDMO Revenue in Topical Drugs CDMO Business (2021-2026)
- 12.9.4 Bora Pharmaceutical CDMO Topical Drugs CDMO Product Portfolio
- 12.9.5 Bora Pharmaceutical CDMO Recent Developments
- 12.10 Ascendia Pharmaceuticals
- 12.10.1 Ascendia Pharmaceuticals Company Information
- 12.10.2 Ascendia Pharmaceuticals Business Overview
- 12.10.3 Ascendia Pharmaceuticals Revenue in Topical Drugs CDMO Business (2021-2026)
- 12.10.4 Ascendia Pharmaceuticals Topical Drugs CDMO Product Portfolio
- 12.10.5 Ascendia Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst